Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Discontinuation of biosimilar infliximab in Japanese patients with rheumatoid arthritis in sustained remission or low disease activity (IFX-SIRIUS STUDY II)
jRCTs071200007Completed
- Sponsor
- Celltrion Healthcare
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of infliximab in rheumatoid arthritis (RA), sponsored by Celltrion Healthcare. Primary endpoint: Clinical relapse rate. Started Jan 2021; status: completed.
02
Drugs
infliximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCTs071200007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071200007.